NCT06533527

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

Randomized Trial of Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 69 (actual)
• Sponsor: The Cleveland Clinic · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV). Primary Outcomes: * Residual gastric volume that precludes adequate endoscopic examination * Residual gastric volume that necessitates premature termination of the endoscopy procedure * Need for endotracheal intubation due to stomach contents. * Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hospital admission Secondary Outcomes: * Presence of any solid food * Presence of moderate liquid content * Increased RGV(Residual Gastric Volume) defined as any amount of solid content or \> 0.8 mL/Kg of fluid content (measured from the aspiration/suction canister). * Differences in primary and secondary outcomes between different medications

Conditions

• Diabetes Mellitus, Type 2
• Obesity
• Gastroparesis

Interventions

Type	Name	Description
DRUG	GLP-1 medication	Continue taking GLP-1 as normally scheduled prior to endoscopy.

Timeline

• Start date: 2024-07-31
• Primary completion: 2025-05-20
• Completion: 2025-05-20
• First posted: 2024-08-01
• Last updated: 2025-12-05
• Results posted: 2025-12-05

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study